JPRN-jRCT2080221090未知3 期
Confirmatory study of BK-4SP in healthy infants.
The Research Foundation for Microbial Diseases of Osaka University, Mitsubishi Tanabe Pharma Corporation0 个研究点目标入组 326 人开始时间: 2010年5月25日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 326
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Age: greater than 3months old ,less than 74 months old
排除标准
- 未提供
研究者
相似试验
已完成
2 期
Phase 2 study of BK1304 in healthy childrePrevention of influenzaJPRN-jRCT2031200156Fuji Hideyuki120
未知
2 期
Phase II study of BK1304 in healthy adultsPrevention of influenzaJPRN-jRCT2080223352The Research Foundation For Microbial Diseases Of Osaka University600
进行中（未招募）
1 期
ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line use of CanakinumabActive systemic manifestations of Systemic Juvenile Idiopathic Arthritis(SJIA)MedDRA version: 19.0Level: PTClassification code 10059176Term: Juvenile idiopathic arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2013-004867-29-DEovartis Pharma Services AG180
进行中（未招募）
1 期
ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line use of CanakinumabActive systemic manifestations of Systemic Juvenile Idiopathic Arthritis(SJIA)MedDRA version: 19.0Level: PTClassification code 10059176Term: Juvenile idiopathic arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2013-004867-29-SEovartis Pharma Services AG180
进行中（未招募）
1 期
ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line use of CanakinumabEUCTR2013-004867-29-BEovartis Pharma Services AG180